(NASDAQ: GILD) Gilead Sciences's forecast annual revenue growth rate of 5.32% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 9.06%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.79%.
Gilead Sciences's revenue in 2026 is $29,443,000,000.On average, 34 Wall Street analysts forecast GILD's revenue for 2026 to be $38,251,890,729,264, with the lowest GILD revenue forecast at $36,181,201,288,560, and the highest GILD revenue forecast at $40,192,231,014,528. On average, 33 Wall Street analysts forecast GILD's revenue for 2027 to be $40,532,380,239,200, with the lowest GILD revenue forecast at $37,418,897,554,976, and the highest GILD revenue forecast at $44,116,361,303,536.
In 2028, GILD is forecast to generate $42,668,864,967,888 in revenue, with the lowest revenue forecast at $37,926,638,550,928 and the highest revenue forecast at $49,686,615,212,672.